How do these partnerships work? Working with Eli Lilly, we co-developed a tool we call Semio, which essentially improves planning and design of clinical trials. It puts electronic health records, patient information and some of our data together in a sophisticated structure that lets people make better decisions about trials. It uses multiple screens. It’s like something from the movie Minority Report, where experts monitor multiple screens of information [while] trying to figure out the most effective way to design a trial among populations of potential patients. It’s something I don’t believe anyone else has in the industry. We’ve taken office space in Indianapolis to further our collaboration on this product. In the case of Lilly, we’re pushing the boundaries of planning and design, but we have great relationships with all major players. For example, Tokyo’s Eisai, which conducted proofof-concept trials with Quintiles, says the compounds developed were produced at half the level budgeted. Solvay used Quintiles’ balanced scorecard toolkit and reduced the total cycle time in clinical studies by 40 percent. We can do this in pieces or jointly, depending upon what customers require. For example, we’re doing interesting work with some organizations looking at outsourcing the entire lifecycle of a molecule, from early in vivo situation all the way to the final product. Our strategy is to work with the major pharmas, as well as biotechs and even organizations in emerging markets. The better the design of, say, a clinical trial, the less likely one will have to go back and rework it. This [approach] also minimizes audits or inspections from the FDA. So, yes, we do reduce costs, but it’s not like saying we’re delivering this Boeing 777 for 10 percent less because each drug, each trial is different. The thing to always remember about drug development is that speed of decision-making and speed associated with the actual execution of the trial is crucial to everybody’s best interests, not [the] least [of which is] the patient’s. We have one study going on in an emerging market that found that delivering the product six months sooner will save 150,000 lives per year.
STATEMENT OF OWNERSHIP U.S. Postal Service Statement of Ownership, Management, and Circulation 1. Publication Title: Chief Executive. 2. Publication No. 431-710. 3. Filing Date:10/1/12. 4. Issue Frequency: Bi-monthly. 5. No. of Issues Published Annually: 6. 6. Annual Subscription Price: $198.00 7. Complete Mailing Address of Known Office of Publication: One Sound Shore Drive-Suite 100, Greenwich,CT 06830 . 8. Complete Mailing Address of Headquarters or General Business Office of Publisher: same. 9. Full Names and Complete Mailing Addresses of Publisher, Editorial Director, and Managing Editor: Marshall Cooper (Publisher); J.P. Donlon (Editorial Director/Editor-in-Chief); address same. 10. Owner: Chief Executive Group, LLC, One Sound Shore Drive-Suite 100, Greenwich, CT 06830; 11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities: Marshall Cooper and Wayne Coooper. 12. Not Applicable. 13. Publication Title: Chief Executive. 14. Issue Date for Circulation Data Below: July/Aug. 2012.15. Extent and nature of Circulation: Requested Mail Subscription a. Total No. of Copies (Net Press Run): 45,773; 45,976. b. Paid and/or Requested Circulation: (1) Paid/Requested Outside-County Mail Subscriptions Stated on Form 3541 (Includes Advertisers’ Proof and Exchange Copies): 22,462; 22,518. (2) Paid In-County Subscriptions: None. (3) Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Non-USPS Paid Distribution: 738; 743 . (3) Other paid or requested distribution outside USPS: None. (4) Other Classes Mailed Through the USPS: None. c. Total Paid and/or Requested Circulation [Sum of 15b(1), (2), (3), and (4)]: 23,200; 23,261. d. Nonrequested Distribution (By Mail and Outside the Mail): 21,708;21,870. e. Free Distribution Outside the Mail (Carriers or Other Means): 865; 845. f. Total Distribution (Sum of 15c and 15e): 45,773; 45,976. g. Copies Not Distributed: 802; 733. h.Total Distribution (Sum of 15f and 15g): 46,575; 46,709. i. Percent Paid and/or Requested Circulation (15c/15fx100): 50.68%; 50.59%
november/december 2012 chiefexecutive.net 15